June 26, 2008

Dear Friends:

I truly regret that I am unable to join you in person today, but my duties in Congress require my absence. However, I would like to take this opportunity to convey my sincere congratulations to the University of Kansas Cancer Center for the new drug Nanotax. The approval of a clinical trial from the Food and Drug Administration for Nanotax is an exciting development in cancer research. It improves our chances for eliminating the burden of cancer and exhibits Kansas as a leader in cancer research.

As someone who was on the front lines of pharmaceutical research for twenty years, I am aware of the enormous impact breakthrough research can have on saving people’s lives. It requires dedication and perseverance, characteristics the Cancer Center at the University of Kansas exuberates. Their mission to eliminate the burden of cancer, and attain National Cancer Institute (NCI) Comprehensive Cancer Center designation is a testament to its devotion to the field.

According to the Center for Disease Control, almost 13,000 new cases of cancer were diagnosed in Kansas and over 5,000 Kansans died of cancer in 2004. These statistics are heartbreaking, but there is hope for the future. The FDA’s approval to initiate a Phase I clinical trial for Nanotax is a development all Kansans can get behind. This form of research can face enormous pressure but the end result has invaluable rewards. Therefore, it is crucial that research continues with steadfast support. On behalf of the Second District of Kansas, I wish you the greatest success in your endeavor.

Very truly yours,

Nancy Boyda
Member of Congress
June 26, 2008

Dear Friends:

I truly regret that I am unable to join you in person today, but my duties in Congress require my absence. However, I would like to take this opportunity to convey my sincere congratulations to the University of Kansas Cancer Center for the new drug Nanotax. The approval of a clinical trial from the Food and Drug Administration for Nanotax is an exciting development in cancer research. It improves our chances for eliminating the burden of cancer and exhibits Kansas as a leader in cancer research.

As someone who was on the front lines of pharmaceutical research for twenty years, I am aware of the enormous impact breakthrough research can have on saving people’s lives. It requires dedication and perseverance, characteristics the Cancer Center at the University of Kansas exuberates. Their mission to eliminate the burden of cancer, and attain National Cancer Institute (NCI) Comprehensive Cancer Center designation is a testament to its devotion to the field.

According to the Center for Disease Control, almost 13,000 new cases of cancer were diagnosed in Kansas and over 5,000 Kansans died of cancer in 2004. These statistics are heartbreaking, but there is hope for the future. The FDA’s approval to initiate a Phase I clinical trial for Nanotax is a development all Kansans can get behind. This form of research can face enormous pressure but the end result has invaluable rewards. Therefore, it is crucial that research continues with steadfast support. On behalf of the Second District of Kansas, I wish you the greatest success in your endeavor.

Very truly yours,

Nancy Boyda
Member of Congress